Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

被引：0
|
作者：
Shumack, Stephen [1 ]
Blauvelt, Andrew [2 ]
Iversen, Lars [3 ]
McBride, Sandy [4 ]
Gooderham, Melinda [5 ,6 ]
Staubach-Renz, Petra [7 ]
Yamauchi, Paul [8 ,9 ]
Staelens, Fabienne [10 ]
Vanvoorden, Veerle [10 ]
White, Katy [10 ]
Gisondi, Paolo [11 ]
机构：
[1] St George Dermatol & Skin Canc Ctr, Kogarah, NSW, Australia
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
[4] Royal Free London NHS Fdn Trust, London, England
[5] Queens Univ, SKiN Ctr Dermatol, Peterborough, ON, Canada
[6] Prob Med Res, Peterborough, ON, Canada
[7] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Mainz, Germany
[8] Dermatol Inst & Skin Care Ctr, Santa Monica, CA USA
[9] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA USA
[10] UCB Pharma, Brussels, Belgium
[11] Univ Hosp Verona, Verona, Italy
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [41] Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial
    Bagel, Jerry
    Nia, John
    Hashim, Peter W.
    Patekar, Manmath
    Hugot, Sophie
    Sheng, Kuan
    Xia, Summer
    Gilloteau, Isabelle
    Blauvelt, Andrew
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB274 - AB274
  • [42] Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial
    Bagel, J.
    Nia, J.
    Hashim, P.
    Patekar, M.
    de Vera, A.
    Hugot, S.
    Sheng, K.
    Xia, S.
    Gilloteau, I.
    Blauvelt, A.
    Lebwohl, M.
    Bian, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 17 - 18
  • [43] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [44] Bimekizumab in patients with moderate-to-severe plaque psoriasis by bodyweight: pooled results from phase III trials
    Pinter, A.
    Strober, B.
    Rosmarin, D.
    Gisondi, P.
    Vanvoorden, V.
    Peterson, L.
    Madden, C.
    de Cuyper, D.
    Warren, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E49
  • [45] Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
    Augustin, Matthias
    Langley, Richard G.
    Warren, Richard B.
    Lebwohl, Mark
    Elewski, Boni
    Crowley, Jeffrey
    Warham, Rhys
    Kaspar, Markus
    Wiegratz, Susanne
    Ciaravino, Valerie
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB184 - AB184
  • [46] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    Armstrong, April W.
    Gooderham, Melinda
    Warren, Richard B.
    Papp, Kim A.
    Strober, Bruce
    Thaci, Diamant
    Morita, Akimichi
    Szepietowski, Jacek C.
    Imafuku, Shinichi
    Colston, Elizabeth
    Throup, John
    Kundu, Sudeep
    Schoenfeld, Steve
    Linaberry, Misti
    Banerjee, Subhashis
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 29 - 39
  • [47] BIMEKIZUMAB EFFICACY BY BODY REGION IN PLAQUE PSORIASIS: COMPARATIVE ANALYSES FROM FOUR PHASE 3/3B STUDIES
    Savage, Laura
    Pinter, Andreas
    Crowley, Jeffrey
    Kerkhof, Peter van de
    Armstrong, April
    Kavanagh, Sarah
    Wiegratz, Susanne
    Hoepken, Bengt
    Warren, Richard B.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [48] DUAL NEUTRALISATION OF INTERLEUKIN (IL)-17A AND IL-17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY
    Blauvelt, Andrew
    Papp, Kim A.
    Merola, Joseph F.
    Gottlieb, Alice B.
    Cross, Nancy
    Madden, Cynthia
    Wang, Maggie
    Cioffi, Christopher
    Griffiths, Christopher E. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1834 - 1834
  • [49] Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
    Bagel, J.
    Blauvelt, A.
    Nia, J.
    Hashim, P.
    Patekar, M.
    de Vera, A.
    Ahmad, K.
    Paguet, B.
    Xia, S.
    Muscianisi, E.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (01) : 135 - 142
  • [50] Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
    Gordon, Kenneth B.
    Sebastian, Michael
    Feldman, Steven R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
12345